MARKET

HELP

HELP

Cybin Inc
NASDAQ
6.70
-0.17
-2.47%
After Hours: 6.70 0 0.00% 17:33 07/13 EDT
OPEN
6.85
PREV CLOSE
6.87
HIGH
7.11
LOW
6.50
VOLUME
2.07M
TURNOVER
--
52 WEEK HIGH
9.12
52 WEEK LOW
3.760
MARKET CAP
415.29M
P/E (TTM)
-2.1959
1D
5D
1M
3M
1Y
5Y
1D
VA, HHS sign MOU to improve cooperation on psychedelic drug trials
TipRanks · 4h ago
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
TipRanks · 6h ago
Weekly Report: what happened at HELP last week (0706-0710)?
Weekly Report · 14h ago
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Seeking Alpha · 1d ago
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD)
TipRanks · 4d ago
HC Wainwright & Co. Maintains Buy on Helus Pharma, Lowers Price Target to $70
Benzinga · 4d ago
Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright
TipRanks · 4d ago
More
About HELP
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Webull offers Cybin Inc stock information, including NASDAQ: HELP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HELP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HELP stock methods without spending real money on the virtual paper trading platform.